Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Glassman

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
JAMA Ophthalmology|April 3, 2020
Are P Values Enough?Adam R Glassman
JAMA|March 13, 2019
Errors in Analysis of Mean Deviations in Study of Photocoagulation vs Ranibizumab for Diabetic RetinopathyAdam R Glassman
JAMA Ophthalmology|June 2, 2017
Results of a Randomized Clinical Trial of Aflibercept vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Is It Time to Retire Your Laser?Adam R Glassman
JAMA Ophthalmology|March 6, 2025
Anti-Vascular Endothelial Growth Factor Options and Questions for Diabetic Eye Disease TreatmentAdam R Glassman
JAMA Ophthalmology|March 1, 2019
Incorrect Data in SupplementAdam R Glassman
JAMA Ophthalmology|August 21, 2015
Considerations for randomizing 1 eye or 2 eyes--replyAdam R Glassman, Michele Melia
JAMA Ophthalmology|September 27, 2014
Randomizing 1 eye or 2 eyes: a missed opportunityAdam R Glassman, Michele Melia
JAMA Ophthalmology|June 16, 2022
Patient-Reported Outcome Measures in a Clinical Trial of the Port Delivery System With RanibizumabWesley T Beaulieu, Adam R Glassman
JAMA Ophthalmology|September 24, 2020
Interpreting Multiple Outcomes of Pupillary Light Reflex in Sport-Related Concussion in AdolescentsWesley T Beaulieu, Adam R Glassman
JAMA Ophthalmology|November 20, 2015
A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor TherapyJeffrey G Gross, Adam R Glassman
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
JAMA Ophthalmology|April 3, 2020
Are P Values Enough?Adam R Glassman
JAMA|March 13, 2019
Errors in Analysis of Mean Deviations in Study of Photocoagulation vs Ranibizumab for Diabetic RetinopathyAdam R Glassman
JAMA Ophthalmology|June 2, 2017
Results of a Randomized Clinical Trial of Aflibercept vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Is It Time to Retire Your Laser?Adam R Glassman
JAMA Ophthalmology|March 6, 2025
Anti-Vascular Endothelial Growth Factor Options and Questions for Diabetic Eye Disease TreatmentAdam R Glassman
JAMA Ophthalmology|March 1, 2019
Incorrect Data in SupplementAdam R Glassman
JAMA Ophthalmology|August 21, 2015
Considerations for randomizing 1 eye or 2 eyes--replyAdam R Glassman, Michele Melia
JAMA Ophthalmology|September 27, 2014
Randomizing 1 eye or 2 eyes: a missed opportunityAdam R Glassman, Michele Melia
JAMA Ophthalmology|June 16, 2022
Patient-Reported Outcome Measures in a Clinical Trial of the Port Delivery System With RanibizumabWesley T Beaulieu, Adam R Glassman
JAMA Ophthalmology|September 24, 2020
Interpreting Multiple Outcomes of Pupillary Light Reflex in Sport-Related Concussion in AdolescentsWesley T Beaulieu, Adam R Glassman
JAMA Ophthalmology|November 20, 2015
A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor TherapyJeffrey G Gross, Adam R Glassman
Pageof 13